Member Info for WeTookPelham

Just to add/amend what I said earlier "...which implies maybe not needed for this stage of the moditope trial? Well at least not yet?"

RE the close date, I wonder if it implies the role is not related to modify trial at all?

https://www.scancell.co.uk/senior-clinical-research-associate-oxford

So that role previously mentioned is on the company website (they seem very inconsistent about posting them on there), but now it seems with a closing date of 05/06, so no immediate urgency, which implies maybe not needed for this stage of the moditope trial? Well at least not yet?

By the way, well said violindog. You'd think we'd have an update by now/very soon.

Anyway...I'm more interested in people's thoughts on the new role?

As per chester18's comment "Question that arises is, which trial ? Bit late for the current ModiFY trial so, What's Next on the list ?"

It's seems a bit vague about the specific platform technolgy(s) involved? Newbie question...Could it be expansion of the already expanded Modify trial? Or is that stage of the trial fully mapped out now? I.e. not subject to change?

https://uk.linkedin.com/jobs/view/senior-clinical-research-associate-at-scancell-ltd-3059711328

Senior Clinical Research Associate
Scancell Ltd Oxford, England, United Kingdom
7 hours ago Be among the first 25 applicants

(Senior) Clinical Research Associate

A unique opportunity for an experienced CRA to join Scancell and gain a depth and breadth of expertise in oncology, immunology and the broader field of biotechnology development.

Job Purpose:
Working within a multidisciplinary team at the cutting-edge of scientific breakthrough, you will act as the primary point of contact for oncologists across the UK and their study teams. You will also ensure the clinical trial is executed at oncology sites to the highest standards.

Key Responsibilities:
• Primary point of contact for leading oncology investigational teams in the UK
• Performs site selection, initiation, interim monitoring and close out
• Leads study start-up and provides local expertise.
• Perform feasibility, site identification, selection and evaluation, supporting initial list of sites and forecasting of patient recruitment
• Provides protocol and related study training to study sites
• Supports Investigator meetings
• Supports patient recruitment initiatives

Knowledge, Experience and Skills required
• Educated to degree level (life or medical science discipline)
• A minimum of 3 years’ experience in the field of clinical research
• Therapeutics experience in oncology and immunotherapy preferred
• Excellent team-working skills with the ability to interact and communicate effectively with professionals in a multi-disciplinary team
• Thorough knowledge of clinical research concepts regarding drug development phases and clinical research methodology

@burble - did you mean you've edited the page, or someone else is?

Thanks @chester18, i forgot about SCLP.GB.PLC. I remember the actual GB.PLC LSE forum board being mentioned on this LSE board a few times before, but can someone tell me what exactly it is? An alternative ticker? Why are trades going through that ticker(?) as well. Is it like Aquis?
https://www.lse.co.uk/ShareTrades.asp?shareprice=SCLP.GB.PL&share=Scancell-Holdings-Plc

Yes C11, did think it was interesting and agree, wonder if any significance about the timing? Worth checking the history, can't click on the users though, do you need a login?
https://en.m.wikipedia.org/wiki/Special:History/Lindy_Durrant
A hopeful/bullish part of me wonders if this is about the conference this week.

...chunky sell (I think), and after hours again I think?
I'm a complete novice when it comes to how the market/brokers handle trades but I saw this comment by emptend:

"29/4/2022
17:01 emptyend: Guessing that someone has swept up the loose stock again....So look forward to news next week."

So was it a buy? But also with a lot of bed and ISA action happening atm is this related to this? I.e. sells pooled together? Someone on here mentioned this before.

https://en.m.wikipedia.org/wiki/Lindy_Durrant

Agree with TF, why would fpd be seen as a bad thing for the SP? That's seems very odd to think that, IMO.

This morning's look like bed & ISAs to me. IMO.

...after the bell. Impatience?

Thanks C11, yeah I did wonder if I imagined it. But IMO it's good that the big gun science wise and the (combined) CEO/CSO are in attendance.

Looks like Professor Durrant is also attending now?

https://www.pegsummit.com/attendees

"Scancell Ltd CSO
Scancell Ltd Principal Scientist, Biodiscovery"

Did I miss that originally, or has she been added since?

Thanks moon party.

As it's so quiet here today, I'm just throwing this out there, but @miavoce, RE your comment:
"The fact that Scancell are presenting their Glycan/Avidimab (Glmab) portfolio at such a prestigious conference must indicate that they are now very confident in the platform. They are putting their goods in the shop window - ready for deals to be done."

It's probably my lack of understanding, but as I mentioned those pharma already in research collaborations for the mabs products would surely want first dibs? But do we know how any licencing would work? Exclusivity etc?

I'm just wondering why they they want to put in the shop window as you put it, it's seems like those that need to know about, know about it (i.e. the recent large European pharma they linked with). Are they looking for more/extra partners? I guess no harm in tapping up other suitors whilst those current ones are still deciding perhaps?

But also, as C7 mentioned, are there more conferences coming up for SCLP? They were quiet on the conference circuit for while weren't they? Something changed?

You'd think those pharmas already in research collaborations with Scancell would want first dibs?
https://www.lse.co.uk/rns/SCLP/scancell-progresses-its-new-anti-glycan-mab-kde9mwc49rra8mh.html
The attendance/presentation is certainly an interesting one.

Yeah looks like every man and his dog are there:
https://www.pegsummit.com/attendees

Mostly US based by the looks of it, with the exception of SCLP and Leeds uni?

https://www.theguardian.com/society/2022/apr/22/like-fingerprints-at-a-scene-study-finds-new-clues-about-causes-of-cancer

Like fingerprints at a crime scene’: study finds new clues about causes of cancer
For first time it is possible to detect patterns in cancers’ DNA – opening up to possible personalised treatments